Variable domains of heavy chain-only antibodies (VHH), also known as nanobodies (Nbs),
are monomeric antigen-binding domains derived from the camelid heavy chain-only …

The field of cancer treatment has evolved significantly over the last decade with the
emergence of next-generation therapeutic antibodies. Conventional treatments like …

Breast cancer is the most common type of cancer in women and the second leading cause
of cancer death in female. Triple-negative breast cancer has a more aggressive proliferation …

Two human proteins involved in the inflammatory cell death, namely Gasdermin D (GSDMD)
and the Mixed Lineage Kinase Domain-Like (MLKL) protein have been engineered to …

Highly specific targeting of dendritic cells in vivo is crucial for the development of effective
tumor nanovaccines. This group recently presented an antibody‐functionalized nanocarrier …

Nanoscale protein materials show increasing applications in biotechnology and
biomedicine, addressing catalysis, drug delivery, or tissue engineering. Although protein …

The bacterial pathogen Acinetobacter baumannii is a leading cause of drug-resistant
infections. Here, we investigated the potential of developing nanobodies that can recognize …

Nanobodies are the smallest known antigen-binding molecules to date. Their small size,
good tissue penetration, high stability and solubility, ease of expression, refolding ability …

NANOBODYⓇ molecules are an innovative class of biotherapeutics based on heavy chain
only VHH immunoglobulins. Much like canonical antibodies, they are prone to the formation …

Histidine-rich peptides confer self-assembling properties to recombinant proteins through
the supramolecular coordination with divalent cations. This fact allows the cost-effective …